Skip to content
mapperlab
← Dashboard
Stock

QTTB

Q32 Bio Inc.
Latest close $5.753 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
3
27 funds tracked
Ever held
6
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024Feb 13, 2025Aug 13, 2025May 15, 2026
Now
3

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$34$5.75-83%
Citadel Advisors re-entered$36$5.75-84%
Two Sigma Investments re-entered$2.67$5.75+115%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management 2× in & out→ $6.30+235%
AQR Capital Management→ $2.16+24%
Point72 Asset Management→ $2.67-93%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Q32 Bio Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
2
Filings · last 90d
5
Total on file
227
Recent SEC buffer
Most recent
Jun 1, 2026

30d / 90d windows measured from Jun 1, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 227 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Q32 Bio Inc.

Annual figures sourced directly from Q32 Bio Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$53.74M
FY2025
Net income
$29.82M
FY2025+162% YoY
EPS (diluted)
$2.42
FY2025+137% YoY
Free cash flow(?)
-$33.54M
FY2025+51% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Q32 Bio Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ4 2025open$2.16$5.75+166%
Two Sigma InvestmentsQ4 2025open$2.16$5.75+166%
Millennium ManagementQ3 2025Q2 2026$1.88$6.30+235%
Renaissance TechnologiesQ3 2025open$1.81$5.75+218%
AQR Capital ManagementQ2 2025Q4 2025$1.74$2.16+24%
Two Sigma InvestmentsQ1 2025Q2 2025$2.67$1.74-35%
Millennium ManagementQ4 2024Q2 2025$36$1.74-95%
Point72 Asset ManagementQ4 2024Q1 2025$36$2.67-93%
Citadel AdvisorsQ3 2024Q4 2024$36$36-2%
Renaissance TechnologiesQ3 2024Q1 2025$34$2.68-92%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.